Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Fulcrum Therapeutics Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units. The portfolio involves 5 distinct examiners. SEAMAN, D MARGARET M is the busiest examiner with 1 pending office action. Since there are 5 distinct examiners for 5 pending office actions, each examiner is responsible for one case.
This spread across 4 distinct art units indicates that the company's biotech filings are subject to varied examination perspectives. Practitioners should monitor the 4 distinct art units for any diverging trends in biotechnology. Coordinating responses across these 5 distinct examiners will be necessary to maintain a unified prosecution strategy for the 5 pending office actions. The lack of examiner overlap suggests that each application requires a unique approach tailored to the individual examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553352 | POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE | HAVLIN, ROBERT H | 71d overdue |
| 18557694 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | LEE, ANDREW P | — |
| 18553317 | MACROCYCLIC AZOLOPYRIDINES | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553352 | POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE | HAVLIN, ROBERT H | 71d overdue |
| 18557694 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | LEE, ANDREW P | — |
| 18553317 | MACROCYCLIC AZOLOPYRIDINES | KENYON, JOHN S | — |
| 17295782 | COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE | EBBINGHAUS, BRIANA NOEL | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1691 | 1 |
| 1626 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18783250 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | SEAMAN, D MARGARET M | 1625 | §112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18557694 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | LEE, ANDREW P | 1691 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18553317 | MACROCYCLIC AZOLOPYRIDINES | KENYON, JOHN S | 1625 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18553352 | POLYMORPHIC FORMS OF (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINE | HAVLIN, ROBERT H | 1626 | §102§103Other | Final Rejection | 71d overdue | Pending | Sep 29, 2023 |
| 17295782 | COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE | EBBINGHAUS, BRIANA NOEL | 1632 | §112 | Non-Final OA | — | Pending | May 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFulcrum Therapeutics Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
D Margaret M Seaman has the most, with 1 of Fulcrum Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
